{"schema_version":"secwatch.filing_event.v1","accession":"0001549595-24-000041","form_type":"8-K","ticker":"NRIX","cik":"0001549595","company_name":"Nurix Therapeutics, Inc.","filed_at":"2024-04-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.920013+00:00","generated_at":"2026-06-04T00:55:39.146928+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Nurix announces first clinical responses in brain for BTK degrader NX-5948","bullets":["NX-5948 detected in CSF from all available samples, showing brain penetration.","CLL patient with CNS involvement achieved partial response by week 24 and cleared tumor cells from CSF.","PCNSL patient with MYC rearrangement had complete regression of three lesions at week 8, but progressed by week 16.","Data presented at AACR 2024; NX-5948 is an oral BTK degrader in Phase 1a/1b for B cell malignancies."],"urls":{"canonical":"https://secwatch.observer/filing/0001549595-24-000041","json":"https://secwatch.observer/filing/0001549595-24-000041.json","markdown":"https://secwatch.observer/filing/0001549595-24-000041.md","text":"https://secwatch.observer/filing/0001549595-24-000041.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1549595/000154959524000041/0001549595-24-000041-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1549595/000154959524000041/nrix-20240409.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T00:55:39.146928+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}